Eli Lilly shares rose again Tuesday, their sixth increase in the past seven sessions. The drugmaker's market cap also closed at a record, $973.8 billion, as Lilly inched closer to the $1 trillion ...

Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump administration regarding the sale of its GLP-1 medication. In a letter to Lilly ...

Nov 21 (Reuters) - Eli Lilly (LLY.N), opens new tab hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse. A more ...

"The cloud that has been casting a shadow over the healthcare industry is slowly lifting. The Eli Lilly agreement, along with the Trump deal with Pfizer last month, is providing investors with much ...

Eli Lilly is continuing its recent pattern of tying disease awareness-raising efforts to major pop cultural moments. The latest high-profile crossovers—which include a starry TV partnership and the ...

Eli Lilly delivered 54% revenue growth in Q3 2025, raised full-year guidance, and remains a defensive haven amid market volatility. LLY's obesity and diabetes franchise, led by Zepbound, Mounjaro, and ...

Silicon Valley’s giants crowd the list of the world’s most valuable companies, but drugmaker Eli Lilly is hot on their heels. The company topped a market capitalization of $1 trillion on Friday, ...

The 150-year-old drugmaker is the first company in health care to hit the milestone. By Rebecca Robbins Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, ...

The booming market for weight-loss drugs has propelled Eli Lilly LLY-0.41%decrease; red down pointing triangle to become the first pharmaceutical company to hit $1 trillion in market capitalization, ...

South Korea’s newest billionaire is Lee Sang-hoon, founder of Seoul-based ABL Bio, after it struck a $2.6 billion licensing and joint research deal with Eli Lilly for its bispecific antibody ...

Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness to compete on price as it tries to claw back a larger share of the US market ...